Researchers at the University of Tennessee Health Sciences Center working with colleagues at the University of New Mexico have identified three drugs already approved for use in humans as possible therapies for the COVID-19 coronavirus..

Based on virtual antiviral screening and in vitro antiviral screening that began in the early months of the COVID-19 pandemic, researchers led by UTHSC's Collin Jonsson, Ph.D., identified zuclopenthixol, nebivolol and amodiaquine as promising therapeutic agents against the virus..

In an article published in ACS Pharmacology \u0026 Translational Science, researchers suggest drugs as possible candidates for testing in future clinical trials to improve the immune response to coronavirus.

Amodiaquine is an older antimalarial drug, zuclopenthixol is an antipsychotic drug, and nebivolol is a blood pressure medicine.

“Particularly in the context of this pandemic, there is an urgent need for high-quality research that can provide critical knowledge of the COVID-19 disease and reliable treatment proposals,” the document says.

“Keeping these caveats in mind, we developed a computational workflow that included independent in vitro validation followed by evaluation of new candidates in the context of available clinical pharmacology data with the aim of proposing suitable candidates for clinical trials at an early stage (incubation and symptomatic phase) SARS-infected patients.

Given the need to improve efficacy and safety, zuclopenthixol, nebivolol and amodiaquine have been suggested as potential candidates for clinical trials against the early phase of SARS-CoV-2 infection, the researchers write..

https: // sundaynews. info /.

Keywords:.